JP2012520295A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520295A5
JP2012520295A5 JP2011553972A JP2011553972A JP2012520295A5 JP 2012520295 A5 JP2012520295 A5 JP 2012520295A5 JP 2011553972 A JP2011553972 A JP 2011553972A JP 2011553972 A JP2011553972 A JP 2011553972A JP 2012520295 A5 JP2012520295 A5 JP 2012520295A5
Authority
JP
Japan
Prior art keywords
methyl
cells
prodrug
chem
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011553972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520295A (ja
JP5793428B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NZ2010/000040 external-priority patent/WO2010104406A1/en
Publication of JP2012520295A publication Critical patent/JP2012520295A/ja
Publication of JP2012520295A5 publication Critical patent/JP2012520295A5/ja
Application granted granted Critical
Publication of JP5793428B2 publication Critical patent/JP5793428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011553972A 2009-03-11 2010-03-11 プロドラッグ形態のキナーゼインヒビターおよび治療におけるそれらの使用 Active JP5793428B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ575490 2009-03-11
NZ57549009 2009-03-11
NZ57945809 2009-09-02
NZ579458 2009-09-02
NZ581170 2009-11-12
NZ58117009 2009-11-12
PCT/NZ2010/000040 WO2010104406A1 (en) 2009-03-11 2010-03-11 Prodrug forms of kinase inhibitors and their use in therapy

Publications (3)

Publication Number Publication Date
JP2012520295A JP2012520295A (ja) 2012-09-06
JP2012520295A5 true JP2012520295A5 (cg-RX-API-DMAC7.html) 2013-05-02
JP5793428B2 JP5793428B2 (ja) 2015-10-14

Family

ID=42728538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011553972A Active JP5793428B2 (ja) 2009-03-11 2010-03-11 プロドラッグ形態のキナーゼインヒビターおよび治療におけるそれらの使用

Country Status (13)

Country Link
US (2) US9073916B2 (cg-RX-API-DMAC7.html)
EP (2) EP3031807A1 (cg-RX-API-DMAC7.html)
JP (1) JP5793428B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110130468A (cg-RX-API-DMAC7.html)
CN (2) CN102348708A (cg-RX-API-DMAC7.html)
AU (1) AU2010221818A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011505A2 (cg-RX-API-DMAC7.html)
CA (1) CA2754808C (cg-RX-API-DMAC7.html)
IL (1) IL214626A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011009034A (cg-RX-API-DMAC7.html)
NZ (2) NZ620000A (cg-RX-API-DMAC7.html)
RU (1) RU2011141121A (cg-RX-API-DMAC7.html)
WO (1) WO2010104406A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
CN102558185B (zh) * 2010-12-09 2016-02-10 中国科学院上海药物研究所 吡啶并吡咯三嗪化合物、其制备方法和用途
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
WO2013152135A1 (en) * 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
CN105796562A (zh) * 2012-09-10 2016-07-27 杨子娇 化合物在制备防治青光眼病的药物中的用途
CN105796569A (zh) * 2012-09-10 2016-07-27 杨子娇 化合物在制备防治青光眼病的药物中的用途
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN103655576A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN103724349A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN102952095A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法
CN103784456A (zh) * 2012-10-31 2014-05-14 韩冰 一类治疗干眼症的化合物及其用途
CN103787986A (zh) * 2012-10-31 2014-05-14 韩冰 一类治疗干眼症的化合物及其用途
CN103804304A (zh) * 2012-11-01 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804305A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804306A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2986294A4 (en) 2013-04-17 2016-11-16 Biopharma Works PROCESS FOR PAIN TREATMENT
EP2986295A4 (en) * 2013-04-17 2016-11-09 Biopharma Works PROCESS FOR PAIN TREATMENT
CN107892684B (zh) * 2013-07-18 2020-05-26 锦州奥鸿药业有限责任公司 喹唑啉衍生物及其药物组合物,以及作为药物的用途
CN107427515B (zh) 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US20160376239A1 (en) * 2015-06-29 2016-12-29 Ontogenesis, Llc N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
CN110809576B (zh) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 Fgfr激酶抑制剂和药物用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
WO2021003339A1 (en) 2019-07-03 2021-01-07 The Regents Of The University Of Colorado, A Body Corporate Amp-activated protein kinase inhibitors and methods of making and using the same
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
WO2022006412A2 (en) 2020-07-02 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Conjugates of ampk inhibitors and protac degraders and related uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236881T1 (de) 1995-08-18 2003-04-15 Auckland Uniservices Ltd Durch strahlung aktivierte cytotoxin therapie
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
ES2279361T3 (es) 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
GB0421294D0 (en) 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
WO2008039087A2 (en) 2006-09-29 2008-04-03 Auckland Uniservices Limited Indoline derivatives and uses thereof
WO2008151253A1 (en) 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии

Similar Documents

Publication Publication Date Title
AU2018256591B2 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
MX2023003410A (es) Forma polimorfica cristalina a de un inhibidor de jak y metodos para su preparacion.
HRP20221301T1 (hr) Inhibitori kras g12c
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
TN2013000394A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine
RU2018131134A (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ
MX2010008101A (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
IL287004B1 (en) Dosage forms and regimens for amino acid compounds
WO2020097400A8 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
JP2023520330A5 (cg-RX-API-DMAC7.html)
CA2611312A1 (en) Organic compounds
CA2749040A1 (en) Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd
RU2016110096A (ru) Новое хинолин-замещенное соединение
MX2017010230A (es) Derivados de mono- y poliazanaftaleno sustituidos y su uso.
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
HK1199879A1 (en) Pde9 inhibitors with imidazo triazinone backbone
AU2010221818A1 (en) Prodrug forms of kinase inhibitors and their use in therapy
MX345802B (es) Forma cristalina de compuesto pirimido [6, 1-a] isoquinolin-4-ona.
RU2008141239A (ru) Соединения тетрагидропиридотиенопиримидина и способы их применения
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung